UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 20.

Wüthrich, R P; Kistler, A D; Rodriguez, Daniel; Kapoor, Sarika; Mei, Changlin (2015). Blood pressure control for polycystic kidney disease. In: Li, Xiaogang. Polycystic kidney disease. Brisbane: Codon Publications, Brisbane, Australia, 95-108.

Wüthrich, R P; Kistler, A D (2015). Blutdruckkontrolle bei Patienten mit polyzystischer Nierenerkrankung. Der Nephrologe, 10:201-206.

Kistler, A D; Wüthrich, R P (2015). Chronische Niereninsuffizienz - welche Therapien können die Progression wirksam verlangsamen. Swiss Medical Forum, 15(11):251-256.

Pavik, I; Jaeger, P; Ebner, L; Poster, D; Krauer, F; Kistler, A D; Rentsch, K; Andreisek, G; Wagner, C A; Devuyst, O; Wüthrich, R P; Schmid, C; Serra, A L (2012). Soluble Klotho and autosomal dominant polycystic kidney disease. Clinical Journal of the American Society of Nephrology, 7(2):248-257.

Kistler, A D; Siwy, J; Breunig, F; Jeevaratnam, P; Scherl, A; Mullen, W; Warnock, D G; Wanner, C; Hughes, D A; Mischak, H; Wüthrich, R P; Serra, A L (2011). A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapy. PLoS ONE, 6(6):e20534.

Pavik, I; Jaeger, P; Kistler, A D; Poster, D; Krauer, F; Cavelti-Weder, C; Rentsch, K M; Wüthrich, R P; Serra, A L (2011). Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate. Kidney International, 79(2):234-240.

Kistler, A D; Schwarz, U; Dalmau, J; Rudiger, A (2010). Laparoscopic epilepsy surgery. Intensive Care Medicine, 36(2):367-368.

Serra, A L; Poster, D; Kistler, A D; Krauer, F; Raina, S; Young, J; Rentsch, K M; Spanaus, K S; Senn, O; Kristanto, P; Scheffel, H; Weishaupt, D; Wüthrich, R P (2010). Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. New England Journal of Medicine, 363(9):820-829.

Wüthrich, R P; Kistler, A D; Serra, A L (2010). Impact of Mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease. Transplantation Proceedings, 42(9 Supp):S44-S46.

Kistler, A D; Serra, A L (2010). Neue diagnostische Aspekte bei zystischen Nierenerkrankungen. Der Nephrologe, 5(5):375-383.

Bolliger, M F; Zurlinden, A; Lüscher, D; Bütikofer, L; Shakhova, O; Francolini, M; Kozlov, S V; Cinelli, P; Stephan, A; Kistler, A D; Rülicke, T; Pelczar, P; Ledermann, B; Fumagalli, G; Gloor, S M; Kunz, B; Sonderegger, P (2010). Specific proteolytic cleavage of agrin regulates maturation of the neuromuscular junction. Journal of Cell Science, 123(Pt 22):3944-3955.

Kistler, A D; Mischak, H; Poster, D; Dakna, M; Wüthrich, R P; Serra, A L (2009). Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. Kidney International, 76(1):89-96.

Kistler, A D; Poster, D; Krauer, F; Weishaupt, D; Raina, S; Senn, O; Binet, I; Spanaus, K; Wüthrich, R P; Serra, A L (2009). Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. Kidney International, 75(2):235-241.

Wüthrich, R P; Serra, A L; Kistler, A D (2009). Autosomal dominant polycystic kidney disease: new treatment options and how to test their efficacy. Kidney & Blood Pressure Research, 32(5):380-387.

Kistler, A D; Poster, D; Wüthrich, R P; Serra, A L (2009). Hydronephrosis in autosomal dominant polycystic kidney disease. Kidney International, 76(12):1297.

Poster, D; Kistler, A D; Krauer, F; Blumenfeld, J D; Rennert, H; Weishaupt, D; Wüthrich, R P; Serra, A L (2009). Kidney function and volume progression in unilateral autosomal dominant polycystic kidney disease with contralateral renal agenesis or hypoplasia: a case series. American Journal of Kidney Diseases, 54(3):450-458.

Serra, A L; Kistler, A D; Poster, D; Krauer, F; Senn, O; Raina, S; Pavik, I; Rentsch, K; Regeniter, A; Weishaupt, D; Wüthrich, R P (2009). Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney disease. Nephrology, Dialysis, Transplantation, 24(11):3334-3342.

Stephan, A; Mateos, J M; Kozlov, S V; Cinelli, P; Kistler, A D; Hettwer, S; Rülicke, T; Streit, P; Kunz, B; Sonderegger, P (2008). Neurotrypsin cleaves agrin locally at the synapse. FASEB Journal, 22(6):1861-73.

Hofbauer, G F L; Marcollo-Pini, A; Corsenca, A; Kistler, A D; French, L E; Wüthrich, R P; Serra, A L (2008). The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. British Journal of Dermatology, 159(2):473-475.

Serra, A L; Kistler, A D; Poster, D; Struker, M; Wüthrich, R P; Weishaupt, D; Tschirch, F (2007). Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study. BMC Nephrology, 8:13.

This list was generated on Mon Jul 24 09:34:35 2017 CEST.